Holland Capital backs Eindhoven-based Sirius Medical in €12M round to improve care for cancer patients

Eindhoven-based Sirius Medical, a surgical marker navigation company, announced that it has secured €12M in a Series B round of funding led by Holland Capital. 

Existing investors BOM Brabant Ventures, Curie Capital, and Team Holmium, and new investor Norgine Ventures, as well as Sirius Medical’s management and team participated in the round.

The Dutch firm says it will use the funds to accelerate the worldwide growth of their product, Pintuition, and support further product development. 

“Having become the fastest growing company in the industry is a clear confirmation of the unique benefits that our technology brings to both patients and physicians,” says Bram Schermers, CEO at Sirius Medical. 

“Supported by this latest funding round I am confident that our highly talented and motivated team will further drive the adoption of Pintuition across the globe,” adds Schermers. 

In 2020, the Dutch company raised €4.4M in a Series A round of funding from a syndicate led by the BOM Brabant Ventures, with co-investors Curie Capital and Holland Capital.

Improving care for cancer patients

Led by CEO Bram Schermers, Sirius Medical aims to improve care for cancer patients by delivering solutions that enable precise and efficient removal of tumours. 

The company’s Pintuition technology provides surgeons with real-time distance and directional navigational guidance to locate tumours accurately. 

With over 100 active centres and over 5,000 successful Pintuition procedures across Western Europe and the US, the company experienced unprecedented growth in revenue in 2022

The Pintuition technology is both CE-marked and FDA cleared.

The Investor

Holland Capital is one of the first independent private equity firms in the Netherlands. Since 1981, the firm has been investing in promising small and medium-sized Dutch businesses with growth ambitions. It has invested in more than 150 SMEs.

“We are excited about the market potential for surgical marker navigation,” says Jan Frens van Giessel, partner at Holland Capital. “We believe that the Pintuition technology and its future innovations will significantly improve surgery of non-palpable tumours for patients, physicians and improve the care for cancer patients.”